Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 8, 2007, Pages 673-675

  Cianfrocca, Mary ^a   Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Combination therapy; Metastatic breast cancer; Polychemotherapy; Single agent

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG ACTIVITY; DRUG RESPONSE; HUMAN; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 34848814488     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0069     Document Type: Article

References (9)

1. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-3460.
2. Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;CD003372.
3. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
4. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic breast cancer (MBC): interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol 2003;22(Suppl 1):Abstract 25.
5. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as front-line therapy for metastatic breast cancer (MBC): first report of overall survival [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 510.
6. Miles D, Vukelja S, Moiseyenko V, et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004;5:273-278.
7. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
8. Smalley RV, Murphy S, Huguley CM, Bartolucci AA. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 1976;36:3911-3916.
9. Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401-2408.